Recent Updates
Recently added Catalysts
TMDX Neutral Sentiment Score: 60/100

TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

Key Takeaway: TransMedics Group, Inc. announced it will report its financial results for the first quarter of 2025 after market close on May 8, 2025. The management team will host a conference call at 4:30 p.m. ET to discuss these results. TransMedics is renowned for its advancements in organ transplant therapy, focusing on improving organ quality and viability assessment for transplantation.

Market Sentiment Analysis

POSITIVE FACTORS

  • TransMedics is expected to release its financial results soon.
  • The company is transforming organ transplant therapy with innovative technology.

Full Press Release Details

ANDOVER, Mass. , April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025 . The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT .
Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domestic callers or (412) 634-6944 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ .
About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact: Brian Johnston Laine Morgan 332-895-3222 [email protected]
SOURCE TransMedics Group, Inc.

21 %

Frequently Asked Questions

When will TransMedics release Q1 2025 financial results?

TransMedics will release its Q1 2025 financial results on May 8, 2025.

How can I participate in the TransMedics conference call?

Call (844) 676-6010 domestically or (412) 634-6944 internationally to join.

When is the TransMedics conference call scheduled?

The conference call is scheduled for May 8, 2025, at 4:30 p.m. ET.

Where can I find the webcast of the conference call?

The webcast will be available in the 'Investors' section of their website.

What does TransMedics specialize in?

TransMedics specializes in portable extracorporeal warm perfusion for organ transplants.

Last updated: Apr 24, 2025